伊布替尼治疗慢性淋巴细胞白血病临床研究进展

Clinical research progress of ibrutinib in the treatment of chronic lymphocytic leukemia

慢性淋巴细胞白血病(CLL)是一种异质性较大的成熟B淋巴细胞肿瘤,成熟淋巴细胞凋亡受抑、克隆性增殖从而聚集在血液、骨髓、脾脏、淋巴结中引起的一类惰性血液肿瘤.目前临床发病原因并未完全明确,环境与职业因素并不占有主要地位,有研究显示长期接触低频电磁场可能与其发病有关,但患者一级和二级亲属淋巴系统恶性肿瘤发病率增高.许多家族尚存在患者后代发病年龄更早、病情更重的现象.近几年来,随着医疗水平的不断进步,慢性淋巴细胞白血病的各种治疗方法相继问世,包括各种新药物.伊布替尼是全球第一个上市的布鲁顿氏酪氨酸激酶(BTK)抑制剂,为更多慢性淋巴细胞白血病患者带来了福音.笔者就伊布替尼在治疗慢性淋巴细胞白血病的临床研究进展作一综述.

Chronic lymphocytic leukemia(CLL) is a heterogeneous mature B lymphocytic tumor. The apoptosis of mature lymphocyte is inhibited and clonal proliferation of mature lymphocyte aggregates in blood,bone marrow,spleen and lymph nodes,resulting in a class of inert hematological tumors. At present,the clinical pathogenesis is not completely clear,environmental and occupational factors do not occupy a major position. Studies have shown that long - term exposure to low - frequency electromagnetic fields may be associated with its incidence,but patients with primary and secondary relatives of lymphatic malignancies increased incidence. Many families still have patients whose age is earlier and the disease is more serious. In recent years,with the continuous improvement of medical level,a variety of treatment methods for chronic lymphoblastic leukemia have emerged,including a variety of new drugs. Ibutinib is the world's first marketed Bruton's tyrosine kinase(BTK) inhibitor,for more patients with chronic lymphoblastic leukemia has brought the gospel. This article reviews the clinical research progress of ibrutinib in treating CLL.